Veru Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Veru de winst en omzet met respectievelijk 6.7% en 40.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 13.4% per jaar.

Belangrijke informatie

6.7%

Groei van de winst

13.4%

Groei van de winst per aandeel

Personal Products winstgroei	26.1%
Inkomstengroei	40.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	05 Nov 2024

Recente toekomstige groei-updates

Recent updates

Is Veru (NASDAQ:VERU) A Risky Investment?

Aug 07

What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

Jul 17

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

May 31

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Jan 09

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Aug 16

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Apr 17

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Feb 14

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Aug 03

Winst- en omzetgroeiprognoses

NasdaqCM:VERU - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2027	11	-65	-72	-50	3
9/30/2026	10	-72	-67	-45	4
9/30/2025	13	-49	-55	-34	5
9/30/2024	14	-40	-12	-22	5
6/30/2024	14	-37	-27	-27	N/A
3/31/2024	13	-39	-40	-40	N/A
12/31/2023	16	-63	-60	-60	N/A
9/30/2023	16	-93	-89	-88	N/A
6/30/2023	15	-126	-100	-99	N/A
3/31/2023	21	-136	-96	-95	N/A
12/31/2022	28	-116	-74	-73	N/A
9/30/2022	39	-84	-48	-48	N/A
6/30/2022	52	-47	-28	-27	N/A
3/31/2022	60	-28	-27	-26	N/A
12/31/2021	61	-16	-26	-25	N/A
9/30/2021	61	7	-16	-16	N/A
6/30/2021	57	0	-15	-15	N/A
3/31/2021	50	0	1	1	N/A
12/31/2020	47	2	1	1	N/A
9/30/2020	43	-19	-2	-2	N/A
6/30/2020	40	-10	-3	-3	N/A
3/31/2020	39	-10	-7	-6	N/A
12/31/2019	36	-13	-7	-6	N/A
9/30/2019	32	-12	-6	-5	N/A
6/30/2019	28	-17	-7	-7	N/A
3/31/2019	24	-22	-11	-11	N/A
12/31/2018	20	-22	-13	-13	N/A
9/30/2018	16	-24	-12	-12	N/A
6/30/2018	14	-21	-8	-8	N/A
3/31/2018	13	-14	N/A	-2	N/A
12/31/2017	13	-11	N/A	0	N/A
9/30/2017	14	-9	N/A	1	N/A
6/30/2017	14	-6	N/A	0	N/A
3/31/2017	15	-4	N/A	-1	N/A
12/31/2016	17	-3	N/A	0	N/A
9/30/2016	22	0	N/A	-2	N/A
6/30/2016	26	3	N/A	1	N/A
3/31/2016	28	3	N/A	0	N/A
12/31/2015	34	5	N/A	-1	N/A
9/30/2015	33	4	N/A	-2	N/A
6/30/2015	31	3	N/A	-1	N/A
3/31/2015	31	3	N/A	0	N/A
12/31/2014	24	2	N/A	1	N/A
9/30/2014	24	2	N/A	4	N/A
6/30/2014	24	10	N/A	1	N/A
3/31/2014	23	9	N/A	8	N/A
12/31/2013	28	12	N/A	12	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat VERU de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat VERU de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat VERU de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van VERU ( 40.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van VERU ( 40.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VERU naar verwachting over 3 jaar hoog zal zijn

Veru Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 16% to US$4.00

Consensus revenue estimates increase by 65%, EPS downgraded

Consensus revenue estimates decrease by 32%, EPS upgraded

Consensus revenue estimates decrease by 44%, EPS upgraded

Consensus revenue estimates increase by 12%

Recent updates

New minor risk - Market cap size

Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek

Veru Receives Notification from The Nasdaq Stock Market

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 16% to US$4.00

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Veru (NASDAQ:VERU) A Risky Investment?

Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024

What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

New major risk - Financial position

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference

Chairman recently sold US$247k worth of stock

Consensus revenue estimates increase by 65%, EPS downgraded

High number of new and inexperienced directors

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Consensus revenue estimates decrease by 32%, EPS upgraded

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

Consensus revenue estimates decrease by 44%, EPS upgraded

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Consensus revenue estimates increase by 12%

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Consensus revenue estimates fall by 60%

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$25.60

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Price target decreased to US$25.60

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Veru FDA AdCom meeting for COVID-19 therapy postponed